Year One showed us exactly
where the opening is.
The signals are clear, the lane is unclaimed, and the window closes Q4 2026. Here’s what the data taught us — and how we move.
The content that earned the most wasn’t the content we posted most. Provider’s Edge earns 3× the engagement of any other pillar — on a fraction of the volume. That’s the signal.
Cold Clinical, Celebrity Halo, Wellness Glow — all taken. Comfort + Science + Warmth sits unclaimed. No competitor has staked it. Jeisys is already built for it.
Structural, not tactical. Rebalance toward what’s already working, claim the positioning lane the market left open, and build the post-purchase infrastructure that turns providers into advocates.
Three postures own the category. One territory sits unclaimed.
Every provider pain point and patient frustration in this chapter points at the same gap. Nobody has staked it yet — and the window closes Q4 2026.
Comfort + Science + Warmth
The intersection of medical-grade outcomes and genuine warmth sits completely unclaimed — in a $5.5B market already moving toward exactly that.
Three postures dominate. One territory — the intersection of medical-grade outcomes and genuine warmth — sits unclaimed.
Cold Clinical
Thermage, Secret RF, Evoke. Navy / silver / chrome. Device-as-hero. Reads as medical infrastructure, not a woman's choice.
Celebrity Halo
Morpheus8, MOXI, Sofwave. Kardashian + Bieber + Aniston. Powered by celebrity heat — but patient sentiment is turning cautionary.
Wellness Glow
HydraFacial, Clear+Brilliant. Owns the sensory floor. Strong on comfort, light on clinical credibility. Doesn't compete on outcomes.
Comfort + Science + Warmth
Medical-grade outcomes delivered with the warmth of a partner brand. Comfort as a real claim. Science as the foundation, not the whole pitch. The audience is already there — no competitor has staked it.
The window is open through Q4 2026 before MOXI extends down or HydraFacial extends up.
Provider Pain Points
What device companies aren't delivering. What that gap costs practices every day.
Abandoned after the sale
The single most consistent complaint in HCP research. Reps push hard to close, then go dark. No community, no assets, no one to call. The device arrives. The support doesn't.
All competitors except a small handful with strong post-purchase programs
Toolkits that look like marketing but don't work like it
Generic brochures and stock images that no patient ever acted on. Solo practices need copy-paste-ready social posts and patient-facing content their existing audience will actually engage with.
Gap deepest atCynosure does practitioner UGC well — most others are weak
A painful device is a reputation problem — and it's not their fault
Pain complaints, grid-mark scarring, fat-loss documentation — all over TikTok and Reddit. The device brand survives the blowback. The solo practice absorbs it.
Gap deepest atMorpheus8 (InMode), Thermage FLX, Sofwave
Training takes days. Most practices don't have days.
Training-heavy onboarding pulls clinical staff offline and pushes the ROI timeline out by months. Device companies price it in. Solo practices pay for it in lost revenue.
Gap deepest atMost legacy platforms — Sciton, Solta, Cutera / Secret RF
They have to sell this upward. Nobody's built the tools for that.
Practice leads sell internally before any device brand shows up. Solo-practice case studies don't survive that conversation. They need chain-level proof: multi-location utilization data, standardized rollout playbooks. Almost no one has built this.
Almost no one does this well — opportunity wide open
Chains scale by training one person. Most brands still train them one by one.
A chain with 8 locations can't pull staff offline 8 times. Train-the-trainer is the only model that scales. Most device companies still don't offer it — which means the economics of onboarding break before the device earns a dollar.
Gap deepest atSciton, Solta, InMode all train per-practice
The ROI math exists. Nobody's built it for chains.
Section 179 and solo-practice ROI tools don't translate. Chain buyers need cross-location utilization math, marketing co-op ROI, and consolidated billing economics. That document doesn't exist yet — so the close relies on intuition instead of evidence.
Gap deepest atUniversal gap across the entire category
They expect a strategic partner. Most device brands show up to close.
Chain buyers expect QBRs, account-level rep relationships, and input on portfolio strategy. Device companies show up to sell. The gap between "vendor" and "partner" is exactly where Jeisys can plant a flag.
Gap deepest atUniversal weakness in the category
The patients are talking. The scores are dropping.
Morpheus8 was the gold standard. It's now the cautionary tale. RealSelf score: 97% → 65% over three years. Pain complaints, grid-mark scarring, fat-loss documentation — all over TikTok and Reddit. Practices riding it out are absorbing blowback that isn't theirs.
Morpheus8 (InMode) practices
Cutera went bankrupt. Now what?
Based on available reporting: Chapter 11 in March 2025, Nasdaq delisting, emerged private in May 2025. For practices on Secret RF, the question isn't if they'll switch — it's when. Provider forums are openly anxious about consumables, tip supply, and software support.
TargetCutera Secret RF, Excel V+, Enlighten practices
Twenty-four years old and still running hot.
Thermage FLX launched in the Jennifer Aniston era. Operators call it physically uncomfortable. Patients call it painful. The pedigree is real. The momentum isn't. DENSITY beats it on every axis — collagen output, comfort, and consistency.
TargetThermage FLX (Solta) practices
The results depend entirely on who's holding the device.
Ultrasound-class devices punish learning curves. Sofwave and Ultherapy results vary heavily by operator — and practices new to the category pay for that inconsistency in patient trust before they ever build proficiency.
TargetSofwave, Ultherapy practices
Patient Pain Points
She already knows what she wants. The category still hasn’t figured out how to give it to her. (MRI Aesthetics, Jul 2025 · 73% women · median age 37 · HHI $145K)
Category Whitespace
Three conversations the audience is already having. Zero device brands showed up.
Collagen Banking
Gift-wrapped for DENSITYPatients in their 20s and 30s are searching "preventative aesthetics" and "banking collagen" right now. No medical-grade device brand owns the term. DENSITY's mechanism IS collagen banking — the brand strategy already names the Collagen Banker sub-segment.
Ozempic / GLP-1 Face
First-mover openGLP-1 use is exploding. Practices are watching facial volume disappear weekly. Filler brands own volume-restoration. No collagen-stimulation brand has stepped up. DENSITY's collagen-stimulation positioning plus the GLP-1 sub-segment = a head start no competitor has.
Aesthetics as Wellness
Full brand frameShe thinks of aesthetics the same way she thinks of Pilates, supplements, and HRT — as a practice, not a procedure. Medical-grade brands still talk in treatments. HydraFacial owns the sensory floor. Nobody has claimed medical-grade-meets-wellness-stack.
True Skin-of-Color Safety
Defensible lanePIH risk in Fitzpatrick IV+ skin is documented across most aesthetic devices. Providers are fielding it. Most brands bury it or avoid it. DENSITY's dual-mode RF and 5-level cooling were engineered for this patient. Pair with the KOL diversity already mapped in personas.
The gap is real. Here's who's failing to fill it — and why that's Jeisys’ opening.
Positioning Map — Comfort vs. Results
Every major competitor plotted on two axes. Jeisys devices land in the unclaimed top-right quadrant — high results, high comfort — that no one else occupies. Positioning reflects Near & Dear's assessment based on Phase 1 research; not a clinical claim.
↑ Hover any dot for competitor context
Every competitor owns one word.
Two territories are still unclaimed.
Every Reddit and RealSelf complaint secretly asks for it: "will this actually work the same way on me?" No one has owned it. DENSITY's real-time impedance calibration is the only device built to deliver it.
MOXI owns "prejuvenation" but can't say "resurfacing." HydraFacial owns "glow" but can't say "CO₂." CoolPeel owns "CO₂" but trades depth for a peel. The only device that can pair "real fractional CO₂" + "10 minutes" + "zero downtime" — and no competitor can follow.
Competitor Landscape by Device Lane
The original — returned to its original maker. Earned confidence, not borrowed credibility.
- 91% RealSelf "Worth It" — category-leading
- 4 RF modes vs. Vivace's 1 and Morpheus8's 1
- Real-time impedance monitoring — comfort engineered in
- Singular focus — not buried inside a parent portfolio
RFMN gold standard turning cautionary. InMode publicly called 2026 a "stabilization year."
- Largest installed base in RF microneedling
- Category-defining brand recognition
- RealSelf "Worth It" 97% → 65% over three years
- Pain, grid-mark scarring, fat-loss documented on TikTok / Reddit
- Single-mode RF — no comfort, depth, or versatility narrative
Feature-led not benefit-led ("500×/sec impedance"). Story doesn't reach patients.
- Real clinical credibility on the spec sheet
- Brand diluted inside Cynosure portfolio alongside XERF
- No singular voice; spec-led messaging skips the patient
"The Vivace Experience" — but RealSelf sentiment undercuts "pain-free" claims.
- Experience-led brand language patients respond to
- Cartessa's 2025 spotlight shifted to EVERESSE
- "Too subtle for the price" is the dominant patient note
- Single-mode RF without depth or comfort proof
Largest legacy RFMN social footprint — but signal has gone quiet since restructuring.
- ~54K followers @secretbycutera — biggest installed loyalty
- Chapter 11 March 2025; emerged private May 2025
- No confirmed 2025–26 hardware launches
- Provider anxiety about consumables and service continuity is acute
"Comfort + depth + versatility." No competitor pairs 4-mode RF with actual comfort data and a 91% RealSelf Worth It score. Morpheus8 has depth but not comfort. Vivace has comfort but not depth. "The original." Potenza is the device that returned to its original maker — earned confidence, not borrowed credibility.
No needles, no downtime. Engineered for the consistency every other RF promises.
- Dual-mode RF (monopolar + bipolar) — no one else pairs both
- Real-time impedance calibration eliminates operator variance
- 5-level cooling — comfort baked into the engineering, not the marketing
- 5× more collagen output, no downtime
Pedigree without momentum. 24+ years old at $2,500–4,000 per session.
- Category legacy — owns the word "tighten"
- Premium price anchor protects their market
- Patient sentiment cites pain and heat
- Monopolar-only, operator-dependent
- No forward momentum — no platform investment
Declining incumbent — Merz is prioritizing injectables, not the device.
- Broad install base, ultrasound visualization
- Widely reported pain
- 12+ month treatment intervals
- Patient sentiment and Merz's investment direction have moved on
K-beauty RF narrative, FDA-cleared Aug 2025. Feature story without real differentiation.
- Recent FDA clearance + K-beauty halo
- 2-session protocol simplicity at $1,800/treatment
- Monopolar bulk-heat only — no scar/texture/depth claim
- Brand diluted inside Cynosure portfolio alongside Genius RF
Celebrity-powered ultrasound — but the results narrative is turning cautionary.
- Kim and Khloé co-sign heat
- Synchronous parallel beam tech, $1,500–3,000/session
- RealSelf: "painful, no results, thinner face regret"
- Ultrasound-only — no RF mechanism, no scar or texture claim
"Consistency." Every Reddit and RealSelf complaint secretly asks: "will this work the same way on me?" Thermage owns "tighten." Sofwave owns "lift." Evoke owns "remodel." No one has claimed the word every patient actually wants. DENSITY's real-time impedance calibration + dual-mode RF is the only device in the lane built to deliver it. Lead: "more collagen, more comfort, more consistency."
Resurfacing in 10. The only fractional CO₂ that pairs real ablation depth with a 10-minute protocol.
- Real CO₂ ablation depth — non-ablative competitors structurally cannot match
- EdgePolish™: 10-minute CO₂ with zero downtime
- Two-tier ladder: EdgePolish™ → Deep Renewal upsell path
- Pairs with HydraFacial — doesn't compete with cleanse-and-glow
Coined "prejuvenation." Celebrity halo carrying it — but ceiling is real.
- Hailey Bieber, Sydney Sweeney, Aniston co-signs
- Owns "prejuvenation" as patient-facing language
- Non-ablative ceiling — cannot claim "real CO₂ resurfacing"
- Requires 3–4 sessions; "MOXI ruined my skin" (melasma flare) documented on RealSelf
- Being absorbed into Sciton's HALO TRIBRID — losing standalone identity
FTX refresh April 2025. Non-ablative by design — structurally bounded.
- Solta legacy + broad existing install base
- RealSelf Worth It fallen to 65%
- PIH in Fitzpatrick IV+ documented
- Non-ablative ceiling cannot reach Edge ONE's CO₂ depth
NewBeauty "Best CO₂" four years running. Fastest-growing direct head-to-head threat.
- Owns the word "CoolPeel"
- 92% RealSelf "Worth It"
- "10-minute CO₂" framing competes directly with EdgePolish™
- Single treatment depth — no glow-tier upsell path
- No structural answer to a two-tier ladder (EdgePolish™ → Deep Renewal)
"Resurfacing in 10." EdgePolish™ is the only device that can legally pair "real fractional CO₂" + "10 minutes" + "zero downtime" in the same sentence. MOXI owns "prejuvenation" but can't say "resurfacing." HydraFacial owns "glow" but can't say "CO₂." CoolPeel owns "CO₂" but trades depth for a peel. Don't attack HydraFacial — reframe the practice menu: "Keep HydraFacial for cleanse-and-glow; add EdgePolish™ for the results patients actually came for."
Patient Complaints · Jeisys Answers
The four complaints driving patients to research alternatives — and the answer Jeisys already has for each one.
Three Strategic Openings · Q3–Q4 2026
Three competitors. Three windows. Move now or watch someone else claim the ground.
The whitespace is mapped. Now here’s what the data is already telling us about how to claim it.
The data told us exactly where to go next.
Year One’s strongest signals point directly at the Year Two strategy. The content that earned the most wasn’t the content we posted most — and that gap is the entire opportunity.
Provider’s Edge content earns 3× the engagement of any other pillar on Instagram — despite being posted less than any other content type. The data is telling you something: B2B narrative is your highest-performing creative territory. Double down.
Category Authority is LinkedIn’s highest-performing pillar at 46.5% engagement — averaging 153 engagements per post. Document posts hit 38–62%. The B2B platform rewards the clinical credibility story. We’re not posting enough of it there.
“DENSITY RF | The Comfortable RF” posted the highest engagement rate in the long-form library. Comfort-forward positioning isn’t just a brand idea — it’s a proven content format.
315 of 704 Instagram Stories originated from practices and reps — and they’re the highest-share format on the account. The provider community is already creating for you. The opportunity is to systematize what’s happening organically.
The Coverage Paradox
We posted most where engagement was lowest. We under-fed the pillars doing the heaviest lifting. This is the structural rebalance year two makes.
Our highest-engagement pillars aren't our highest-volume pillars. Human Comfort and Real Results sit at roughly 10% of content volume despite top performance on YouTube and Instagram. These are our cleanest competitive moats. We're under-feeding them.
Pillar Performance: Volume vs. Engagement
Content volume (% of all posts) vs. engagement rate (likes + comments + saves + shares / impressions). The gap between bars is the rebalancing opportunity.
Voice from the Audience
Real comments. Zero prompting. Pulled from the @jeisys_us inbox, May 2025–May 2026.
“Wait is that the Density?? I’ve heard the results are insane”
Instagram · Unprompted · Patient
“I swear Potenza changed my life! I suffered from cystic acne for years… this device is a miracle.”
Instagram · Unprompted · Patient
“Just finished my 3rd session and the tightening around my jawline is insane”
Instagram · Density Patient Journey
“Painless skin tightening is the holy grail! we cant wait to offer this to our clients”
Instagram · Provider · Unprompted
“Just had my first Density treatment last week! Zero downtime and no pain is a real thing”
Instagram · Patient · First Treatment
Demand Signal
Patients in Houston, LA, NYC, the Pacific Northwest, Greenwich CT, PA, and San Diego are DMing to ask where they can find a provider. The network isn’t there yet.
Direct Messages · May 2025–May 2026
The data is teaching us where to lean in.
Provider Amplification Is the Engine
When providers carry the message, it lands harder than when we do it ourselves. That’s consistent across every surface we measured.
Comfort and Real Results Are Underleveraged
Both sit at roughly 10% of content volume despite top performance on YouTube and Instagram — and they’re our cleanest competitive moats per the April 2026 Competitor Audit. No competitor has staked either lane.
Edge ONE Needs Launch-Year Scaffolding
DENSITY practices have a complete support kit. Edge ONE practices bought in February without one — no consultation guide, no front desk script, no patient Q&A. The content is starting to move. The partnership infrastructure is the next layer.
Measurement Framework · Retire Vanity Metrics
Stop optimizing for likes. These four signals connect content investment to business outcomes.
Provider Personas
Click any persona to expand the full profile.
DENSITY entry device. Easy to integrate, NP-administered. The biggest gap to fill is post-purchase support — this is exactly where "Business BFF" (Jeisys' documented voice character — the rep who knows your practice) makes its money.
Portfolio addition for collagen / no-downtime gap. Edge ONE's 10-min EdgePolish™ fits high-throughput practice economics perfectly.
Potenza gold-standard RF microneedling, peer-validated. Real-time impedance monitoring is the clinical differentiator she evaluates before anything else.
Potenza for surgical-patient retention. Edge ONE for resurfacing adjunct. Both carry the surgical-grade clinical credibility this persona demands before signing any paperwork.
Patient Persona
She's already in the market — and already frustrated by how it talks to her.
4 Sub-Segments
"Build your collagen now, thank yourself later." Pre-juvenation seekers. Self-care framing, not aging-prevention. → DENSITY
"Real results, real lives." Natural-looking, no-downtime. Self-care-as-investment mindset. → DENSITY + Edge ONE
"Restore what GLP-1 takes back." Rapid facial volume loss. Already in the provider system. Doctor-positive. → DENSITY preventative
"No needles. No fillers. Just your skin, working with you." Low-tox lifestyle, HRT-aware, "luxury granola." → DENSITY + Edge ONE
Persona → Product Fit
Which device leads for each persona — and why the fit is structural, not incidental.
Now that you know who they are —
watch how they move.
Every provider persona and patient archetype has a decision journey. Each one has a moment where Jeisys either wins the room or loses it.
Now that you know who they are — here’s exactly how they move from stranger to advocate.
Five personas. Six stages. Everything your rep needs to walk in prepared.
This tool is built for your reps — a quick reference for who they're walking into and exactly what to say at each stage. For leadership, it surfaces the strategic logic behind every play: why we prioritize each persona, what the conversion friction is, and what's currently missing from the toolkit.
Select a persona to see the play
The category has gaps.
This one belongs to Jeisys.
Here's how we take it.
The audience is already rewarding the content we're under-producing. No competitor has claimed the Comfort + Science + Warmth lane. The products are built for it. The window closes Q4 2026. Three plays operationalize that opening — sequenced, owned, and measurable.
Rebalance the Pillar Mix by Channel
Pull volume out of Confident Science on Instagram (where it earns 19% engagement) and push into Real Results and Comfort (where both top-perform despite only 10% of volume). Channel-aware targets, not flat targets. LinkedIn keeps Confident Science — it’s rewarded there (47% engagement for Category Authority).
Build the Structured Provider-Creator Program
Move from informal practitioner UGC to a formal 45/40/15 architecture: 45% provider-creator content, 40% owned @jeisys_us, 15% sales team. Recruit 8–10 provider partners with light briefs and cross-tag rules. Target engagement rate above 7% (vs. 4.08% for branded sales content).
Add the Post-Purchase Business BFF Layer
Build the partnership infrastructure the homepage promises. Edge ONE practice support kit on parity with DENSITY. KOL toolkit for all three devices. /providers section with Section 179 as a gated download. This is what makes the “Business BFF” positioning real instead of just brand language.
The sale is the beginning.
Everything after is where the partnership earns its name.
Every device sale opens five retention windows. The brands that close them earn the word partner. The ones that don’t get replaced.
Retention isn’t a follow-up program. It’s the proof that the “Business BFF” promise is real — and the moment providers stop doubting and start advocating.
Every claim. Two versions. One source.
The Messaging Platform v2.3 governs every approved claim across DENSITY, Potenza, and Edge ONE. Each claim is built twice — once for the provider conversation, once for the patient. Each clinical stat cites its source. Each trademark has a usage rule. This is how Near & Dear ensures brand consistency at scale.
| The Claim | B2B Version | B2C Version |
|---|---|---|
| DENSITY collagen output | Delivers up to 5× more collagen than monopolar RF alone — meaning more structural improvement, better skin quality, and results patients can see and feel.* | Up to 5× more collagen than older RF treatments* — firmer, smoother, healthier-looking skin. |
| Potenza patient satisfaction | 91% RealSelf "Worth It" score — one of the highest ratings in the RF microneedling category. Use in sales conversations as third-party social proof. | 91% of patients say it's worth it. That's not a claim — that's a crowd. |
| EdgePolish™ positioning | The anytime 10-minute skin polish — fast to perform, easy to protocol, and a natural upsell from peels and HydraFacials. | A 10-minute polish that leaves skin glowing. No downtime, no prep — just photo-ready skin. |
*Collagen data: International Journal of Molecular Sciences, PMC8950306. All claims sourced per Messaging Platform v2.3 · February 2026.
The full research library.
Every finding in this document traces back to one of these deliverables. Final versions will be available for download at handoff.
Near & Dear · Prepared for Jeisys Medical North America · April 2026 · Confidential